117 related articles for article (PubMed ID: 32404709)
1. PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics.
Sonni I; Caron J; Kishan AU; Muthusamy VR; Calais J
Clin Nucl Med; 2020 Jul; 45(7):e309-e310. PubMed ID: 32404709
[TBL] [Abstract][Full Text] [Related]
2.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
3. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
4. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
Chen W; Lee Z; Awadallah A; Zhou L; Xin W
Diagn Pathol; 2020 Jul; 15(1):92. PubMed ID: 32703222
[TBL] [Abstract][Full Text] [Related]
5. Ureteral Metastasis From Prostate Cancer: A PSMA PET Pitfall.
Chaussé G; Skinnider B; Crook J; Black P; Abikhzer G; Probst S
Clin Nucl Med; 2020 Sep; 45(9):689-691. PubMed ID: 32558720
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
7. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
8. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
9. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
Matsuda M; Ishikawa E; Yamamoto T; Hatano K; Joraku A; Iizumi Y; Masuda Y; Nishiyama H; Matsumura A
J Neurooncol; 2018 Jul; 138(3):581-589. PubMed ID: 29524126
[TBL] [Abstract][Full Text] [Related]
10. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
12. PSMA expression on neovasculature of solid tumors.
Van de Wiele C; Sathekge M; de Spiegeleer B; De Jonghe PJ; Debruyne PR; Borms M; Beels L; Maes A
Histol Histopathol; 2020 Sep; 35(9):919-927. PubMed ID: 32282924
[TBL] [Abstract][Full Text] [Related]
13. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
14. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
15. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.
Gomez E; Tran PT; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
Clin Nucl Med; 2019 Apr; 44(4):e313-e314. PubMed ID: 30789396
[TBL] [Abstract][Full Text] [Related]
16. An
Dietlein F; Hohberg M; Kobe C; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.
Wernicke AG; Kim S; Liu H; Bander NH; Pirog EC
Appl Immunohistochem Mol Morphol; 2017 Apr; 25(4):271-276. PubMed ID: 26862945
[TBL] [Abstract][Full Text] [Related]
18. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma.
Haemels M; Jentjens S; Cleeren F; Sciot R; Lambert J; Van Laere K; Goffin K
Hell J Nucl Med; 2020; 23(1):79-80. PubMed ID: 32222733
[TBL] [Abstract][Full Text] [Related]
19. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
